FDA Standards Should Emphasize Larger Trials, Lipicky Tells ACC
Executive Summary
FDA should move toward the Cardio-Renal Drug Products Division's requirement for extremely large trials as an approval standard, former Division Director Raymond Lipicky, MD, said